phenazine

(redirected from perphenazine)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

phenazine

[′fen·ə‚zēn]
(organic chemistry)
C6H4N2C6H4 Yellow crystals, melting at 170°C; slightly soluble in water, soluble in alcohol and ether; used as chemical intermediate and to make dyes.
Mentioned in ?
References in periodicals archive ?
The fact that perphenazine works by reactivating a protein shut down in cancer cells is itself novel in the drug development field.
Simultaneous spectrophotometric determination of chlorpromazine, perphenazine and acetopromazine by use of kinetic wavelength pair method.
3] Ireland F A, Loch W E, Worthy K, Anthony R V, Effects of bromocriptine and perphenazine on prolactin and progesterone concentration in pregnant pony mares during late gestation, J Reprod Fertil, 92 (1990) 179.
The psychopharmacology of phenothiazine compounds: a comparative study of the effects of chlorpromazine, promethazine, trifluoperazine and perphenazine in normal males.
The CHD risk dropped slightly among patients using Perphenazine Oral, Risperidone, and Ziprasidone.
The scientists studied olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone, and found that seventy-four percent of the 1432 patients in the study were unable to stay on the neuroleptics for eighteen months owing to the drugs inefficacy or intolerable side effects or for other reasons.
For a patient who presents for evaluation before pregnancy on a low dose of an atypical antipsychotic as an adjunct to a mood stabilizer, it may make sense to switch to an antipsychotic for which more reproductive safety data are available, such as perphenazine.
The CATIE Trial examined the effectiveness of a number of antipsychotics, comparing four second-generation antipsychotics (olanzapine, risperidone, quetiapine and ziprasidone) with perphenazine, a first-generation antipsychotic.
Overall, the atypical antipsychotics studied failed to show superior efficacy or compliance compared to the first generation drug perphenazine.
It's worth noting that in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, a landmark study sponsored by the National Institute of Mental Health that compared the typical antipsychotic perphenazine with the newer atypicals, patients with TD were not assigned to perphenazine, a "mid-potency" typical.